Nintedanib

Nintedanib inhibits multiple receptor tyrosine kinases—VEGFR, FGFR and PDGFR—by blocking their intracellular kinase activity. This prevents downstream signaling that promotes fibroblast proliferation, extracellular matrix deposition, and new blood‑vessel formation, thereby reducing fibrotic tissue and tumor vascular support.

The exact dose of Nintedanib is determined by the prescribing physician based on the specific indication, patient characteristics and any concomitant therapies. Dosing recommendations are provided in the product label and should be followed as directed by a qualified healthcare professional.

The safety of Nintedanib during pregnancy and lactation has not been established. It is classified as unknown for pregnancy, and the drug should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended while taking Nintedanib.

To request Nintedanib, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

For idiopathic pulmonary fibrosis, the primary alternative is pirfenidone, another antifibrotic agent. Nintedanib targets a broader range of tyrosine kinases, offering a different safety profile and may be preferred in patients who cannot tolerate pirfenidone’s gastrointestinal side effects. Choice between agents depends on individual patient factors and physician judgment.

Nintedanib tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or other humid environments.

Nintedanib is taken orally as a tablet, usually with a full glass of water. It can be taken with or without food, but patients are advised to follow any specific instructions from their prescriber. Swallow the tablet whole; do not crush, split, or chew it unless directed otherwise.

The most serious adverse events include severe liver injury (marked elevation of liver enzymes or hepatitis), cardiovascular complications such as arterial thromboembolism or myocardial infarction, and rare gastrointestinal perforation. Patients should report any signs of jaundice, chest pain, sudden abdominal pain, or unusual bleeding promptly.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any of its excipients. It should be avoided in individuals with active bleeding, uncontrolled hypertension, severe hepatic impairment, or those receiving strong CYP3A4 inhibitors without dose adjustment. Pregnant or breastfeeding women should also refrain from use unless absolutely necessary.